Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Transplantation

Personalizing induction therapy in kidney transplantation

Nature Reviews Nephrology volume 5, pages 619–620 (2009)Cite this article

Induction therapy with rabbit anti-thymocyte globulin is preferable to induction with daclizumab in renal transplant recipients at high immunological risk. These findings provide additional support to the idea that personalized immunosuppressive regimens should be developed in renal transplant recipients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. US Department of Health and Human Services 2007 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997–2006 [online], (2009).

  2. Webster, A. C., Playford, E. G., Higgins, G., Chapman, J. R. & Craig, J. C. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77, 166–176 (2004).

    Article  CAS  Google Scholar 

  3. Noël, C. et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J. Am. Soc. Nephrol. 20, 1385–1392 (2009).

    Article  Google Scholar 

  4. Brennan, D. C., Daller, J. A., Lake, K. D., Cibrik, D. & Del Castillo, D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355, 1967–1977 (2006).

    Article  CAS  Google Scholar 

  5. Patlolla, V., Zhong, X., Reed, G. W. & Mandelbrot, D. A. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am. J. Transplant. 7, 1832–1842 (2007).

    Article  CAS  Google Scholar 

  6. Mulgaonkar, S. et al. Continuing 24 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin, and basiliximab) with tacrolimus, mycophenolate mofetil, and a rapid steroid withdrawal in renal transplantation [abstract]. Am. J. Transplant. 9 (Suppl. 2), 282 (2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, New York Presbyterian—Weill Cornell Medical College, New York, NY, USA

    Meredith J. Aull

  2. Department of Medicine & Transplantation Medicine, New York Presbyterian—Weill Cornell Medical College, New York, NY, USA

    Manikkam Suthanthiran

Authors
  1. Meredith J. Aull
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manikkam Suthanthiran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manikkam Suthanthiran.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aull, M., Suthanthiran, M. Personalizing induction therapy in kidney transplantation. Nat Rev Nephrol 5, 619–620 (2009). https://doi.org/10.1038/nrneph.2009.164

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2009.164

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing